The ICMR chief is concerned about the safety of molnupiravir.

  • Jan. 6, 2022, 1:33 p.m.

Antiviral drug molnupiravir, which lately were given approval from the drug regulator and is being released through numerous neighborhood drug makers, has severe protection issues, and accordingly has now not been protected in the country wide Covid-19 medical protocol advocated through the health ministry, the Indian Council of Medical Research (ICMR) director general Balram Bhargava stated.
Bhargava said the Covid-19 task force has debated whether or not to include the drug inside the Covid-19 treatment protocol however determined against it due to issues.
“The US has approved it only based totally on 1,433 sufferers with a 3% discount in mild ailment when given in slight instances. However, we need to remember that this drug has major safety concerns. It can reason teratogenicity, mutagenicity , and it could additionally motive cartilage harm and also can be destructive to muscle tissues,” Bhargava stated.
“More importantly, if this drug is given to a person or a lady, birth control has for use for 3 months, as the child conceived all through that length may additionally have troubles with teratogenic impacts. So, it isn't covered in the countrywide scientific protocol, the WHO has now not covered it, nor has the United Kingdom,” he brought.
Teratogenicity is the potential to cause defects in a growing foetus, while mutagenicity refers to everlasting transmissible modifications in the shape of genetic material of cells.
Bhargava further pointed out that there are concerns about children, pregnant and lactating girls, the ones in reproductive age, soft tissue damage, history of infections and vaccinations when this drug is being prescribed.
Molnupiravir, originally advanced by way of pharma organisation Merck, had to begin with claimed 50% reduction in hospitalisation or demise in sufferers.

Author : Rajdhani Delhi Representative

Rajdhani delhi representative

Related News